RMX Biopharma Co., Ltd (Headquarters in Hangzhou, China, CEO: RuiPing Dong, RMX), which licensed AskAt’s COX-2 inhibitor AAT-076 for pain indications in People’s Republic of China (China), submitted an investigational new drug (IND) application to the State Food and Drug Administration and Supervision Authority of China (CFDA) has been accepted.

With the CFDA’s acceptance of the AAT-076 IND, AskAt will receive a payment according to the terms of the License Agreement executed between RMX and AskAt as a result of achieving this milestone.  RMX will continue to develop AAT-076 for a new chronic pain therapy in China based on the pharmacological efficacies and superior safety previously demonstrated in preclinical studies as well as in human clinical trials in the USA.